Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients
Viruses · 28.04.2023 · 15 (5) · 1076
DOI: 10.3390/v15051076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 28.04.2023. Verfasst von Cathrin Kodde und 7 weiteren Autor:innen. Beteiligte Einrichtung: Germany Department of Respiratory Diseases, Lungenklinik Heckeshorn, Helios Hospital Emil-von-Behring, 14165 Berlin, Germany. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helios Center for Research and Innovation (HCRI).
Abstract (Originalsprache)
Background
Even though several therapeutic options are available, COVID-19 is still lacking a specific treatment regimen. One potential option is dexamethasone, which has been established since the early beginnings of the pandemic. The aim of this study was to determine its effects on the microbiological findings in critically ill COVID-19 patients.
Methods
A multi-center, retrospective study was conducted, in which all the adult patients who had a laboratory-confirmed (PCR) SARS-CoV-2 infection and were treated on intensive care units in one of twenty hospitals of the German Helios network between February 2020–March 2021 were included. Two cohorts were formed: patients who received dexamethasone and those who did not, followed by two subgroups according to the application of oxygen: invasive vs. non-invasive.
Results
The study population consisted of 1.776 patients, 1070 of whom received dexamethasone, and 517 (48.3%) patients with dexamethasone were mechanically ventilated, compared to 350 (49.6%) without dexamethasone. Ventilated patients with dexamethasone were more likely to have any pathogen detection than those without (p < 0.026; OR = 1.41; 95% CI 1.04–1.91). A significantly higher risk for the respiratory detection of Klebsiella spp. (p = 0.016; OR = 1.68 95% CI 1.10–2.57) and for Enterobacterales (p = 0.008; OR = 1.57; 95% CI 1.12–2.19) was found for the dexamethasone cohort. Invasive ventilation was an independent risk factor for in-hospital mortality (p < 0.01; OR = 6.39; 95% CI 4.71–8.66). This risk increased significantly in patients aged 80 years or older by 3.3-fold (p < 0.01; OR = 3.3; 95% CI 2.02–5.37) when receiving dexamethasone.
Conclusion
Our results show that the decision to treat COVID-19 patients with dexamethasone should be a matter of careful consideration as it involves risks and bacterial shifts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Germany Department of Respiratory Diseases, Lungenklinik Heckeshorn, Helios Hospital Emil-von-Behring, 14165 Berlin, Germany.
- Department of Infectious Diseases and Respiratory Medicine, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany.
- Medical Faculty, University of Bonn, 53113 Bonn, Germany.
- Department of Cardiology, Heart Center Leipzig at University of Leipzig, 04289 Leipzig, Germany.
- Division of Infectious Diseases and Prevention, Helios Hospitals, 47166 Duisburg, Germany.
- Center for Clinical and Translational Research, Helios Universitätsklinikum Wuppertal, University of Witten/Herdecke, 42283 Wuppertal, Germany.
ORCID-Profile: Andreas Bollmann, Ralf Kuhlen, Irit Nachtigall
Förderung
- Helios Center for Research and Innovation (HCRI)
Zitieren
APA
Kodde, C., Timmen, F., Hohenstein, S., Bollmann, A., Bonsignore, M., Kuhlen, R., Nachtigall, I., & Tasci, S. (2023). Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients. Viruses, 15(5), 1076. https://doi.org/10.3390/v15051076
Vancouver
Kodde C, Timmen F, Hohenstein S, Bollmann A, Bonsignore M, Kuhlen R, et al. Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients. Viruses. 2023;15(5):1076. doi:10.3390/v15051076
BibTeX
@article{Kodde2023,
author = {Kodde, Cathrin and Timmen, Finja and Hohenstein, Sven and Bollmann, Andreas and Bonsignore, Marzia and Kuhlen, Ralf and Nachtigall, Irit and Tasci, Selcuk},
title = {Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients},
journal = {Viruses},
year = {2023},
volume = {15},
number = {5},
pages = {1076},
doi = {10.3390/v15051076}
}
EUVIMED